Posted by Michael Wonder on 11 Sep 2024
Health Canada approves AbbVie's Constella (linaclotide) for the treatment of functional constipation in paediatric patients 6 to 17 years of age
10 September 2024 - Submission is based on positive Phase 3 study data demonstrating linaclotide (72 mcg) resulted in increases in frequency of spontaneous bowel movements in children and adolescents aged 6 to 17 years.
AbbVie today announced that Health Canada has approved Constella (linaclotide) as a once daily oral treatment for children and adolescents 6 to 17 years of age with functional constipation.
